Collegium Pharmaceutical, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Collegium Pharmaceutical, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Collegium Pharmaceutical, Inc. do? Business model and key facts
Get the full picture of Collegium Pharmaceutical, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees (FY): 423
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Stocks related to Collegium Pharmaceutical, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Collegium Pharmaceutical, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Collegium Pharmaceutical, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
